MAZE (Maze Therapeutics) Interest Expense: $-0.87 Mil (TTM As of Mar. 2026)


MAZE Maze Therapeutics Inc MAZE
14 GF Score
Price $31.79
! 2 Warning Signs
View Full Analysis

What is Maze Therapeutics Interest Expense?

Maze Therapeutics MAZE +1.68% 14 Interest Expense is $-0.87 Mil as of Mar. 2026. GuruFocus rates MAZE with a GF Score™ of 14/100. The stock has 2 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Maze Therapeutics's interest expense for the three months ended in Mar. 2026 was $ -0.87 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.87 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Maze Therapeutics's Operating Income for the three months ended in Mar. 2026 was $ -26.55 Mil. Maze Therapeutics's Interest Expense for the three months ended in Mar. 2026 was $ -0.87 Mil. Maze Therapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Maze Therapeutics  (NAS:MAZE) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Maze Therapeutics's Interest Expense for the three months ended in Mar. 2026 was $-0.87 Mil. Its Operating Income for the three months ended in Mar. 2026 was $-26.55 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was $56.39 Mil.

Maze Therapeutics's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Maze Therapeutics did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Maze Therapeutics Interest Expense Historical Data

* Premium members only.

The historical data trend for Maze Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Maze Therapeutics Interest Expense Chart

Maze Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Interest Expense
0.00 0.00 0.00 0.00

Maze Therapeutics Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.87
MAZE
14GF Score
Maze Therapeutics Inc MAZE
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Maze Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.87 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of $-0.87 Mil mean?
Maze Therapeutics (MAZE) has a Interest Expense of $-0.87 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Maze Therapeutics and its competitors.
Is Maze Therapeutics' Interest Expense too high?
Maze Therapeutics' current Interest Expense is $-0.87 Mil. Overall, Maze Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Maze Therapeutics' Interest Expense compare to AVBP and DMRA?
Maze Therapeutics' Interest Expense of $-0.87 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Maze Therapeutics and its competitors. Maze Therapeutics's current Interest Expense is $-0.87 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maze Therapeutics stock overvalued right now?
Maze Therapeutics (MAZE) has a current Interest Expense of $-0.87 Mil. The current Interest Expense is $-0.87 Mil. Maze Therapeutics' overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Maze Therapeutics (MAZE), the current Interest Expense is $-0.87 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Maze Therapeutics Business Description

Address 171 Oyster Point boulevard, Suite 300, South San Francisco, CA, USA, 94080
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
14GF Score

Get the complete analysis for MAZE

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.79
Price